Rutgers Optimizes Innovation (ROI) Program

罗格斯大学优化创新 (ROI) 计划

• 批准号: 10022340
• 负责人: STEVEN K. LIBUTTI
• 金额: $ 100万
• 依托单位: RUTGERS BIOMEDICAL/HEALTH SCIENCES-RBHS
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-23 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10022340
• 关键词: Abbreviations; Academia; Address; Arts; Biocompatible Materials; Biomedical Engineering; Biomedical Research; Biomedical Technology; Businesses; Clinical; Collaborations; Conscious; Dental; Development; Diagnostic; Discipline; Discipline of Nursing; Disease; Diverse Workforce; Engineering; Evaluation; Fostering; Funding; Future; Government; Health; Healthcare; Incubators; Industry; Infrastructure; Innovation Corps; Institutes; Laboratories; Lead; Leadership; Malignant Neoplasms; Mentors; Mission; Modeling; New Jersey; Pathogenesis; Pathway interactions; Patient Rights; Patients; Personal Satisfaction; Philosophy; Precision therapeutics; Probability; Process; Public Health; Public Health Schools; Research; Research Institute; Resources; School Nursing; Schools; Science; Societies; Solid; Technology; Therapeutic; Time; Training; Translating; Translational Research; Universities; Vision; base; care outcomes; commercialization; cost effective; design; disease heterogeneity; education resources; improved; innovation; medical schools; member; next generation; population health; precision medicine; product development; programs; success; translational medicine; treatment response

Project Summary/Abstract The Rutgers Optimizes Innovation (ROI) Program will provide a vertically integrated mechanism to swiftly uncover promising biomedical product discoveries, and seamlessly guide the innovator through the commercialization process with financial and regulatory, IP protection, mentoring, management, and educational resources. Drawing on the biomedical/bioengineering sciences across Rutgers and on the solid expertise of the Office of Research Commercialization (ORC), we will integrate our strengths to uncover, develop and commercialize discoveries that improve health and well-being, and train the next generation of innovators. The ROI Program comprises a cooperative of Rutgers University and affiliates that includes the schools of engineering, arts and sciences, schools of medicine, nursing, dental science, public health, and research institutes and centers, industries, incubators, funders and policymakers. All entities provide significant resources to the ROI Program and have contributed to the planning, development, and leadership composition of the cooperative. Based in one of the most productive states with respect to commercialization of health-related discoveries (assets), the ROI Program will serve as a platform for translating biomedical discoveries into marketable products. Our REACH Hub will identify innovative health-related technologies by using the expertise of the NCI-funded Cancer Institute of NJ (CINJ), the Rutgers Institute for Translational Medicine and Science (RITMS, lead of the NCATS-funded CTSA) and the Biomaterials Center, funded by NSF and DOD. These technologies will be evaluated for commercialization feasibility, especially with respect to providing precision therapy to tackle an unmet need created by the heterogeneity of disease pathogenesis and response to treatment. Addressing such unmet needs will provide assets tailored to patients’ therapeutic responses that ultimately improves population health. The ROI Program will provide a streamlined and harmonized infrastructure that will enhance commercialization of academic discovery. The educational programs embedded in the ROI Program will provide our innovators with hands-on, practical training in product development and start-up requirements, while also training a diverse workforce in biomedical innovation by leveraging, coalescing and repurposing current resources, including I- Corps and iJOBS. Implementing a unique project management and mentoring program comprised of industry, disease-state and content experts will also enhance innovators’ opportunity for success. Embracing a Fail Fast Philosophy assures the technology will be developed in a cost-effective and market-conscious manner. Across all Aims, the ROI Program will collaborate with the REACH Consortium to build on their advances in platforms for commercialization, technology review, and training, and provide the Consortium with our expertise and commitment to serve as an active participating member. Importantly, evaluation milestones and metrics are planned in all aspects of the ROI Program to assure continuous quality assessment, improvement and sustainability.

项目总结/摘要 罗格斯大学优化创新（ROI）计划将提供一个垂直整合机制，以迅速 发现有前途的生物医学产品发现，并无缝引导创新者通过 商业化流程，包括财务和监管、知识产权保护、指导、管理和教育 资源利用罗格斯大学的生物医学/生物工程科学和 研究商业化办公室（ORC），我们将整合我们的优势，以发现，开发和 将改善健康和福祉的发现商业化，并培养下一代创新者。的 ROI计划由罗格斯大学和附属机构组成，其中包括以下学校： 工程、艺术和科学、医学院、护理、牙科科学、公共卫生和研究 研究所和中心、行业、孵化器、资助者和政策制定者。 所有实体都为ROI计划提供了重要的资源，并为规划、开发、 和合作社的领导组成。位于最具生产力的州之一， 商业化的健康相关的发现（资产），投资回报率计划将作为一个平台，翻译 将生物医学发现转化为可销售的产品。我们的REACH中心将识别与健康相关的创新 技术通过使用NCI资助的新泽西州癌症研究所（CINJ），罗格斯研究所的专业知识， 转化医学和科学（RITMS，NCATS资助的CTSA的领导）和生物材料中心， 由国家科学基金会和国防部资助这些技术将被评估商业化的可行性，特别是与 关于提供精确治疗以解决疾病异质性造成的未满足需求 发病机制和对治疗的反应。解决这些未满足的需求将提供适合患者需求的资产。 最终改善人群健康的治疗反应。 投资回报计划将提供一个简化和协调的基础设施，以提高商业化 学术发现。投资回报率计划中嵌入的教育计划将为我们的创新者提供 与动手，在产品开发和启动要求的实际培训，同时也培训了多样化的 生物医学创新的劳动力，通过利用，合并和重新利用现有资源，包括我， 公司和iJOBS实施一个独特的项目管理和指导计划，包括行业， 疾病状态和内容专家也将增加创新者的成功机会。拥抱快速失败 理念确保技术将以具有成本效益和市场意识的方式开发。跨 所有目标，投资回报率计划将与REACH联盟合作，以他们在平台方面的进步为基础， 商业化，技术审查和培训，并为财团提供我们的专业知识和承诺， 作为一个积极的参与者。重要的是，在所有方面都规划了评价里程碑和衡量标准 投资回报率计划，以确保持续的质量评估，改进和可持续性。